Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
Tissue Eng Part B Rev. 2010 Jun;16(3):305-29. doi: 10.1089/ten.TEB.2009.0590.
Injury of articular cartilage due to trauma or pathological conditions is the major cause of disability worldwide, especially in North America. The increasing number of patients suffering from joint-related conditions leads to a concomitant increase in the economic burden. In this review article, we focus on strategies to repair and replace knee joint cartilage, since knee-associated disabilities are more prevalent than any other joint. Because of inadequacies associated with widely used approaches, the orthopedic community has an increasing tendency to develop biological strategies, which include transplantation of autologous (i.e., mosaicplasty) or allogeneic osteochondral grafts, autologous chondrocytes (autologous chondrocyte transplantation), or tissue-engineered cartilage substitutes. Tissue-engineered cartilage constructs represent a highly promising treatment option for knee injury as they mimic the biomechanical environment of the native cartilage and have superior integration capabilities. Currently, a wide range of tissue-engineering-based strategies are established and investigated clinically as an alternative to the routinely used techniques (i.e., knee replacement and autologous chondrocyte transplantation). Tissue-engineering-based strategies include implantation of autologous chondrocytes in combination with collagen I, collagen I/III (matrix-induced autologous chondrocyte implantation), HYAFF 11 (Hyalograft C), and fibrin glue (Tissucol) or implantation of minced cartilage in combination with copolymers of polyglycolic acid along with polycaprolactone (cartilage autograft implantation system), and fibrin glue (DeNovo NT graft). Tissue-engineered cartilage replacements show better clinical outcomes in the short term, and with advances that have been made in orthopedics they can be introduced arthroscopically in a minimally invasive fashion. Thus, the future is bright for this innovative approach to restore function.
由于创伤或病理状况导致的关节软骨损伤是全世界致残的主要原因,尤其是在北美地区。患有与关节相关疾病的患者人数不断增加,导致经济负担相应增加。在这篇综述文章中,我们重点介绍了修复和替代膝关节软骨的策略,因为膝关节相关残疾比任何其他关节都更为普遍。由于广泛应用的方法存在不足,骨科界越来越倾向于开发生物学策略,其中包括自体(即马赛克plasty)或同种异体骨软骨移植物、自体软骨细胞(自体软骨细胞移植)或组织工程软骨替代物的移植。组织工程软骨构建体是一种极具前途的膝关节损伤治疗方法,因为它们模拟了天然软骨的生物力学环境,并且具有更好的整合能力。目前,已经建立并在临床上广泛研究了多种基于组织工程的策略,作为常规技术(即膝关节置换和自体软骨细胞移植)的替代方法。基于组织工程的策略包括将自体软骨细胞与 I 型胶原、I/III 型胶原(基质诱导的自体软骨细胞移植)、HYAFF 11(Hyalograft C)和纤维蛋白胶(Tissucol)联合植入,或与聚乙二醇酸共聚物和聚己内酯联合植入切碎的软骨(软骨自体移植系统),并使用纤维蛋白胶(DeNovo NT 移植物)。在短期内,组织工程软骨替代物显示出更好的临床效果,并且随着骨科领域的进步,它们可以以微创的方式通过关节镜进行引入。因此,这种恢复功能的创新方法前景光明。